The way SARS-CoV-2 mutates in immunocompromised patients to escape Paxlovid could help chemists design better drugs that are more difficult for the virus to sidestep.
Columbia researchers have found why babies are susceptible to repeated bouts of common respiratory infections—but also have a unique weapon to fight off new pathogens that healthy adults lack.
Patients with mpox who were treated with the antiviral drug tecovirimat had similar outcomes regardless of HIV status, find researchers at Columbia University and Weill Cornell Medicine.
The COVID pandemic transformed students’ education but also imparted profound experiences that students say will make them stronger practitioners and leaders.
Columbia health care workers tell us about the pandemic’s toll on their lives and what CUIMC is doing to alleviate the burden. Emotional support, self-care, and instilling hope are key.
New insights by Columbia researchers into MIS-C, a rare but serious complication of COVID in children, may lead to faster diagnosis and better treatment.
COVID vaccines and monoclonal antibody treatments offer less protection against new omicron subvariants, a new study from researchers at Columbia and University of Hong Kong finds.
Columbia researchers could receive up to $9.4 million to learn about long COVID in children and young adults as part of NIH’s REsearching COVID to Enhance Recovery (RECOVER) initiative.
A common virus that causes no harm in most people may be a danger to organ transplant recipients and other immunocompromised people, Columbia University researchers have found.
A study reports that the brains of a small sample of patients who died of COVID display some of the same molecular changes found in the brains of people with Alzheimer's disease.
Computer modeling of the omicron wave by Mailman's Jeffrey Shaman suggests case numbers may subside as quickly as they climbed, peaking by mid-January in New York City.